Article
New antibiotics in clinical trials for Clostridium difficile
Expert Review of Anti-infective Therapy
(1016)
Abstract
This article reviews the preclinical and clinical studies of cadazolid, LFF571, ridinilazole, and surotomycin. The advantages that these antibiotics may have in the treatment of CDI is compared with current therapies metronidazole, vancomycin, and fidaxomicin. Expert commentary: The antibiotics examined have the potential to improve rates of CDI treatment without recurrence. We anticipate that one or more of these medications will be approved within five years.
Disciplines
Publication Date
Summer July 25, 1016
Citation Information
Eric Slayton, Abigail Hay, Charles K. Babcock and Timothy E. Long. "New antibiotics in clinical trials for Clostridium difficile" Expert Review of Anti-infective Therapy (1016) Available at: http://works.bepress.com/charles-babcock/2/